A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia.

Trial Profile

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2018

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Registrational
  • Acronyms ZENITH
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 03 Feb 2018 Results assessing the long-term safety, tolerability, and efficacy of treatment with brexpiprazole flexible-dose 1-4 mg/day, were published in the International Journal of Neuropsychopharmacology.
    • 05 Sep 2017 According to results presented at the 30th ECNP Congress, a protocol was amended to reduce the study duration from 52-weeks to 26 weeks
    • 03 Apr 2016 Status changed from recruiting to completed as reported by European ClinicalTrials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top